China's drug administration on Wednesday warned consumers not to purchase illegally imported cancer drugs online, as most of the drugs are fake, reports the state news agency Xinhau. 12 June 2014
In women with advanced (or metastatic) breast cancer, treatment with the breast cancer drug trastuzumab, Swiss drug major Roche’s Herceptin, is associated with prolonged survival but also increases the risk of developing heart problems, a new systematic review shows. 12 June 2014
US drug major Eli Lilly (NYSE: LLY) says the Phase III REACH trial of Cyramza (ramucirumab) in patients with hepatocellular carcinoma (or liver cancer) did not meet its primary endpoint; overall survival favored the Cyramza arm but was not statistically significant. Lilly’s shares dipped 1.2% in pre-market trading. 12 June 2014
Taiwanese drugmaker ScinoPharm Taiwan and Taiwan-based drug developer TaiGen Biotechnology have signed a manufacturing contract for the clinical supply of the API of burixafor, a new chemical entity discovered and developed by TaiGen. 11 June 2014
US cancer drug developer Celsion Corp has entered into a definitive asset purchase agreement with EGEN, a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases. 10 June 2014
Dutch/Belgian preclinical stage biotech company arGEN-X, has entered into a partnership with The Leukemia & Lymphoma Society, the world's largest voluntary health agency dedicated to blood cancer, which is headquartered in the USA. 10 June 2014
German family-owned drugmaker Grunenthal is investigating the efficacy and safety of the new analgesic cebranopadol for the treatment of severe chronic pain and peripheral neuropathic pain. 10 June 2014
US biotech firm Immunomedics says that IMMU-132, its antibody-drug conjugate (ADC) for solid cancer therapy, has received orphan drug status from the Office of Orphan Products Development of the US Food and Drug Administration for the treatment of pancreatic cancer. 10 June 2014
Certain targeted therapies enjoy extensive but incomplete coverage in Brazil and Mexico through complex mechanisms, according to research by Decision Resources Group. 10 June 2014
USA-based Pharmacyclics says that the US Food and Drug Administration has accepted for filing its supplemental New Drug Application to support the review of Imbruvica (ibrutinib) in the treatment of patients with chronic lymphocytic leukemia and small lymphocytic lymphoma who have received at least one prior therapy for a full approval. 9 June 2014
US generics major Mylan has launched carboplatin injection, 50mg/5ml, in multi-dose vials, which is the generic version of Bristol-Myers Squibb's Paraplatin injection, in the USA. 9 June 2014
USA-based Momenta Pharmaceuticals says that its novel oncology candidate, necuparanib (formerly M402), has received orphan drug designation from the US Food and Drug Administration for the treatment of pancreatic cancer. 9 June 2014
The Canadian subsidiary of USA-based injectable generic drugs specialist Hospira has refuted press reports regarding its supply and pricing strategy with regard to the cancer drug paclitaxel. 8 June 2014
Delayed disease progression is one of the greatest unmet needs in the first-line treatment of advanced ovarian cancer (CaO), in addition to median overall survival (MOS), according to Decision Resources Group. 6 June 2014
US biotech firm Halozyme Therapeutics saw its shares rise after revealing that the US Food and Drug Administration has removed the clinical hold on patient enrollment and dosing of PEGPH20 in the ongoing Phase II trial evaluating PEGPH20 in patients with pancreatic cancer permitting the study to resume under a revised protocol. 5 June 2014
The France-based Gustave Roussy comprehensive cancer center and Anglo-Swedish drug major AstraZeneca have entered into a joint strategic alliance focussed on early oncology drug development. The partners will develop a joint strategic collaboration plan that will be overseen by a joint steering committee. 5 June 2014
The findings released at the 2014 American Society of Clinical Oncology (ASCO) conference in Chicago have caused something of a stir. Among these were early-stage results with US pharma giant Merck & Co’s pembrolizumab, the latest in a new generation of treatments that prevent cancers shielding themselves from the immune system. 3 June 2014
Anglo-Swedish drug major AstraZeneca provided an update on the rapid development of its oncology pipeline at a briefing for analysts and investors yesterday, as data from over 40 scientific abstracts related to AstraZeneca and subsidiary MedImmune investigational medicines were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago. 3 June 2014
Among the latest important research results presented at the 2014 prestigious annual meeting of the American Society of Clinical Oncology (ASCO) meeting taking place in Chicago, were presentations on US drug major Bristol-Myers Squibb’s already-marketed Yervoy (ipilimumab) and investigational agent nivolumab, two drugs that have been forecast as achieving potential sales of as much as $7 billion for the company. 2 June 2014
Swiss drug major Novartis today presented results from a pivotal Phase III trial showing a 37% improvement in progression-free survival (PFS) when using the investigational compound LBH589 (panobinostat). 2 June 2014
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024